Free Trial
NASDAQ:ICCC

ImmuCell (ICCC) Stock Price, News & Analysis

ImmuCell logo
$3.58
-0.03 (-0.83%)
(As of 11/1/2024 ET)

About ImmuCell Stock (NASDAQ:ICCC)

Key Stats

Today's Range
$3.56
$3.65
50-Day Range
$3.53
$4.14
52-Week Range
$3.34
$5.59
Volume
24,668 shs
Average Volume
18,817 shs
Market Capitalization
$28.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ImmuCell Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
13th Percentile Overall Score

ICCC MarketRank™: 

ImmuCell scored higher than 13% of companies evaluated by MarketBeat, and ranked 930th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImmuCell is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImmuCell is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ImmuCell has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about ImmuCell's valuation and earnings.
  • Percentage of Shares Shorted

    0.18% of the float of ImmuCell has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmuCell has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmuCell has recently decreased by 29.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ImmuCell does not currently pay a dividend.

  • Dividend Growth

    ImmuCell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.18% of the float of ImmuCell has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmuCell has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmuCell has recently decreased by 29.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    ImmuCell has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, ImmuCell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.60% of the stock of ImmuCell is held by insiders.

  • Percentage Held by Institutions

    Only 13.47% of the stock of ImmuCell is held by institutions.

  • Read more about ImmuCell's insider trading history.
Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

ICCC Stock News Headlines

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
ImmuCell Corporation (ICCC)
See More Headlines

ICCC Stock Analysis - Frequently Asked Questions

ImmuCell's stock was trading at $5.09 at the beginning of the year. Since then, ICCC shares have decreased by 29.7% and is now trading at $3.58.
View the best growth stocks for 2024 here
.

ImmuCell Co. (NASDAQ:ICCC) issued its quarterly earnings results on Tuesday, August, 13th. The biotechnology company reported ($0.20) EPS for the quarter. The biotechnology company had revenue of $5.47 million for the quarter. ImmuCell had a negative trailing twelve-month return on equity of 16.35% and a negative net margin of 17.44%.

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

Last Earnings
8/13/2024
Today
11/02/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ICCC
Employees
75
Year Founded
N/A

Profitability

Net Income
$-5,780,000.00
Pretax Margin
-17.42%

Debt

Sales & Book Value

Annual Sales
$23.22 million
Book Value
$3.23 per share

Miscellaneous

Free Float
7,316,000
Market Cap
$28.04 million
Optionable
Not Optionable
Beta
0.56

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:ICCC) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners